Smoking Addiction – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Smoking Addiction – Pipeline Review, H2 2017’, provides an overview of the Smoking Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smoking Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Smoking Addiction

The report reviews pipeline therapeutics for Smoking Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Smoking Addiction therapeutics and enlists all their major and minor projects

The report assesses Smoking Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Smoking Addiction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Smoking Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smoking Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aradigm Corp

AstraZeneca Plc

Axsome Therapeutics Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

CoMentis Inc

Embera NeuroTherapeutics Inc

Invion Ltd

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Lotus Pharmaceutical Co Ltd

NAL Pharmaceuticals Ltd

Pfizer Inc

Selecta Biosciences Inc

Sopharma AD

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Smoking Addiction Overview

Smoking Addiction Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Smoking Addiction Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smoking Addiction Companies Involved in Therapeutics Development

Aradigm Corp

AstraZeneca Plc

Axsome Therapeutics Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

CoMentis Inc

Embera NeuroTherapeutics Inc

Invion Ltd

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

Lotus Pharmaceutical Co Ltd

NAL Pharmaceuticals Ltd

Pfizer Inc

Selecta Biosciences Inc

Sopharma AD

Zynerba Pharmaceuticals Inc

Smoking Addiction Drug Profiles

(bupropion hydrochloride + dextromethorphan hydrobromide) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(metyrapone + oxazepam) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKR-214 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amitifadine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-8529 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-1.4979 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canquit Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTS-21 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JLP-1603 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-39393406 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nadolol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFL-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nicotine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nicotine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nicotine bitartrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06413367 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-070 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRN for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Smoking Addiction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoking Addiction Dormant Projects

Smoking Addiction Discontinued Products

Smoking Addiction Product Development Milestones

Featured News & Press Releases

May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention

Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet

Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis

Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation

Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation

Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform

Jan 29, 2014: FDA clears path for “Smoking Cessation” clinical trial of INV102 (nadolol)

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL

Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs

Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint

Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation

Jan 12, 2012: Inverseon Focuses On Smoking Cessation As Initial Indication For INV102

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Smoking Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Smoking Addiction Pipeline by Aradigm Corp, H2 2017

Smoking Addiction Pipeline by AstraZeneca Plc, H2 2017

Smoking Addiction Pipeline by Axsome Therapeutics Inc, H2 2017

Smoking Addiction Pipeline by Bionex Pharmaceuticals LLC, H2 2017

Smoking Addiction Pipeline by Bioprojet SCR, H2 2017

Smoking Addiction Pipeline by CoMentis Inc, H2 2017

Smoking Addiction Pipeline by Embera NeuroTherapeutics Inc, H2 2017

Smoking Addiction Pipeline by Invion Ltd, H2 2017

Smoking Addiction Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Smoking Addiction Pipeline by Johnson & Johnson, H2 2017

Smoking Addiction Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Smoking Addiction Pipeline by NAL Pharmaceuticals Ltd, H2 2017

Smoking Addiction Pipeline by Pfizer Inc, H2 2017

Smoking Addiction Pipeline by Selecta Biosciences Inc, H2 2017

Smoking Addiction Pipeline by Sopharma AD, H2 2017

Smoking Addiction Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Smoking Addiction Dormant Projects, H2 2017

Smoking Addiction Dormant Projects, H2 2017 (Contd..1), H2 2017

Smoking Addiction Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Smoking Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports